Key result
ICDs reduce mortality in high-risk patients with non-ischaemic dilated cardiomyopathy.
Why the study?
Despite evidence from multiple randomized trials that ICDs reduce mortality in high-risk NICM patients, NICE guidance excludes NICM patients from ICD recommendations, creating clinical and commissioning challenges.
Do implantable cardioverter defibrillators reduce mortality in high-risk patients with non-ischaemic dilated cardiomyopathy?
Do implantable cardioverter defibrillators reduce mortality in high-risk patients with non-ischaemic dilated cardiomyopathy?
This review provides guidance on the use of ICDs in high-risk NICM patients, an area where evidence shows mortality benefit but specific NICE guidance is lacking.
Supports ICD consideration in high-risk non-ischaemic cardiomyopathy; leaves open updated NICE guidance and prospective confirmation.
Patients with non-ischaemic dilated cardiomyopathy (NICM) are at significant risk of sudden cardiac death. Multiple randomised trials have shown that implantable cardioverter defibrillators (ICDs) reduce mortality in high-risk patients with NICM. However, despite this, the National Institute for Health and Clinical Excellence specifically excluded patients with NICM from its updated guidance concerning ICD use. This lack of guidance poses clear problems for both clinicians managing patients with NICM and those who commission healthcare services. This review aims to help guide clinicians in this difficult, high-cost and high-risk area.
No takes yet. Share an insight, caveat, or question.
Scott et al. (2010) conducted a review in non-ischaemic dilated cardiomyopathy (NICM). implantable cardioverter defibrillators (ICDs) was evaluated. Implantable cardioverter defibrillators (ICDs) reduce mortality in high-risk patients with non-ischaemic dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: